[
  {
    "company": "AstraZeneca",
    "published_date": "2026-02-03",
    "title": "Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-02-03",
    "title": "Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-02-02",
    "title": "Imfinzi perioperative regimen recommended for approval in the EU by  CHMP for patients with early gastric and gastroesophageal cancers",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-02-02",
    "title": "AstraZeneca begins trading on the New York Stock Exchange",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-01-30",
    "title": "AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-01-29",
    "title": "AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-01-20",
    "title": "AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-01-08",
    "title": "AstraZeneca appoints Joris Silon as Head of Investor Relations",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "AstraZeneca",
    "published_date": "2026-01-06",
    "title": "Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-05",
    "title": "Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-04",
    "title": "Novo Nordisk files annual report with the SEC",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-04",
    "title": "Novo Nordisk initiates 2026 share repurchase programme",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-04",
    "title": "Novo Nordisk has published its annual report for 2025",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-03",
    "title": "Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-03",
    "title": "Novo Nordisk releases 2026 sales and operating profit outlook",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-02-02",
    "title": "Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-01-31",
    "title": "New employee representative on the Board of Directors of Novo Nordisk A/S",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-01-20",
    "title": "Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes",
    "category": null,
    "url": null,
    "full_text": null
  },
  {
    "company": "novonordisk",
    "published_date": "2026-01-05",
    "title": "Novo Nordisk's Wegovy\u00ae pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America",
    "category": null,
    "url": null,
    "full_text": null
  }
]